Linvoseltamab Elicits Deep Responses in Late-Stage R/R Multiple Myeloma

Linvoseltamab elicited responses with acceptable safety in patients with relapsed/refractory multiple myeloma, including difficult-to-treat subsets

Related Keywords

United States ,New York ,Americans ,Sundar Jagannath ,Tisch Cancer Institute ,Clinical Myeloma Program At Perlmutter Cancer Center ,International Staging System ,Multiple Myeloma ,Mount Sinai ,African Americans ,Blood Cancers ,Clinical Myeloma Program ,Perlmutter Cancer Center ,Linvoseltamab ,Myeloma ,Linker Mm1 Study ,Bispecific Antibody ,Bbs ,Taacr ,Aacr Annual Meeting ,